Organisation paid for research Program year 2025 Source: CMS Open Payments

Arlington Nephrology PA

Neither a doctor nor a teaching hospital

Research payments

$144,244

63 payments

Through program year 2025, Arlington Nephrology PA is reported as receiving $144,244 in research payments, across 63 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $1,771 19
2024 Research $12,128 2
2023 Research $36,275 11
2022 Research $12,620 1
2021 Research $24,405 14
2020 Research $57,045 16

Breakdown

Who paid Research payments · program years 2020–2025
  1. Gilead Sciences, Inc. $77,538 29 payments
  2. Pfizer Inc. $41,278 10 payments
  3. Biogen, Inc. $11,815 1 payment
  4. Akebia Therapeutics Inc $7,931 3 payments
  5. Lexicon Pharmaceuticals, Inc. $3,912 1 payment
  6. Boehringer Ingelheim International GmbH $1,642 16 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $129 3 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 1 Openlabel Nonrandomized Study to Investigate the Safety and PK Following Multiple Oral Doses of Pf07321332 Nirmatrelvirritonavir in Adult Participants With Covid19 and Severe Renal Impairment Either on Hemodialysis Or Not on Hemodialysis $41,278 10 payments
  2. A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON (FALCON) $11,815 1 payment
  3. MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease $11,602 1 payment
  4. MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease $10,087 1 payment
  5. A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects $7,931 3 payments
  6. MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease $6,650 1 payment
  7. MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease $5,437 1 payment
  8. MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease $4,586 1 payment
  9. MOSAIC - A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease $4,494 1 payment
  10. Efc-14875 $3,912 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record